Results 101 to 110 of about 636,170 (221)

Visible‐Light‐Initiated, Nickel‐Catalyzed Aminocarbonylation of Alkynyl Iodides to 2‐Ynamides

Advanced Synthesis &Catalysis, Volume 368, Issue 19, 1 October 2026.
Visible light initiates a nickel‐catalyzed aminocarbonylation of alkynyl iodides, enabling the synthesis of 2‐ynamides under low carbon monoxide pressure. The method operates under mild conditions, tolerates a broad substrate scope, and proceeds through a light‐triggered nickel(I)/nickel(III) carbonylative pathway.
Michael Weiser, Alexander Frischauf, Berthold Stöger, Ertan Turhan, Dennis Kurzbach, Katharina Bica‐Schröder   +5 more
wiley   +1 more source

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

American Journal of Hematology, Volume 101, Issue 10, Page 2546-2556, October 2026.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir, Ahmed Sayed, Dae Hyun Lee, Sanam Ghazi, Mustafa M. Houmsse, Saad Badat, Abdul Moeed, Avirup Guha, Daniel Addison, Narendranath Epperla   +9 more
wiley   +1 more source

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 [PDF]

Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies.
Brown, Robert J, Soni, Rajesh Kumar, Han, Cuijuan, Sievers, Quinlan, Gajewski, Stefan, Mi, Xiaoli, Noviski, Mark, Kim, Won Jun, Reddy, Panga Jaipal, Mato, Anthony R, Abdel-Wahab, Omar, Rhodes, Joanna M, Tsai, Daniel, Bourcier, Jessie, Chirino, Alexandra, Notti, Ryan Q, Hansen, Gwenn M, Bousquet, Hugo, Kane, Tim, Sondhi, Anya K, Pena-Velasquez, Camila, Wang, Eric, Tan, Ying Siow May, Montoya, Skye, Affer, Maurizio, Nawaratne, Vindhya, Pardo, Gabriel, Alencar, Alvaro, Roeker, Lindsey E, Mehta, Sanjoy, Yung, Stephanie, Urban, Aleksandra, Auger, Paul, Lu, Hao, Linley, Adam, Iuliano, James N, Jahn, Jacob, Gessner, Melissa, Zelenetz, Andrew D, Ye, Jordan, Taylor, Justin, Barrientos Risso, Carla, Powers, Janine, Pardo, Alejandro, Thompson, Meghan C, Bravo, Brandon, Skånland, Sigrid S, Garippa, Ralph, Brathaban, Nivetha, Guiducci, Cristiana, Mukerji, Ratul, Sanchez Garcia de Los Rios, Mateo, Totiger, Tulasigeri M   +52 more
core   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways

Journal of Neuroinflammation
Background Bruton’s tyrosine kinase (BTK) is an intracellular signaling enzyme that regulates B-lymphocyte and myeloid cell functions. Due to its involvement in both innate and adaptive immune compartments, BTK inhibitors have emerged as a therapeutic ...
Julie Langlois, Simona Lange, Martin Ebeling, Will Macnair, Roland Schmucki, Cenxiao Li, Jonathan DeGeer, Tania J. J. Sudharshan, V. Wee Yong, Yun-An Shen, Christopher Harp, Ludovic Collin, James Keaney   +12 more
doaj   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors

Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown.
Jahan Rahman, Samantha Sekeres, Ya-Wen Lu, Anthony R. Mato, Justin Taylor, Meghan C. Thompson, Allison Cool, Xiaoli Mi, Jennifer Elechko, Hugo Bousquet, Tim Kong, Nell Narasappa, Jordan Ye, Emel Ficici, May Tan, Stefan Gajewski, Sarah Whelan, Christopher B. Phelps, Alvaro Alencar, Gwenn M. Hansen, Quinlan Sievers, Eduardo Bravo, James N. Iuliano, Maxim I. Maron, Omar Abdel-Wahab, Shruti Bhatt, Mark D. Ewalt, Mateo Sanchez Garcia De Los Rios, Yuhan Wang, Erica N. Lamkin, Prioty Islam, Lizbeth Mendoza Navarrete, Nivetha Brathaban, Lindsey Roeker, Mark A. Noviski, Ratul Mukerji, Hao Lu, Ryan Q. Notti   +37 more
core   +1 more source

Building an Interleukin‐10‐Producing Identity: How B Cells Acquire Interleukin‐10 Competence and How Plasma Cell Differentiation Consolidates This Program

Immunological Reviews, Volume 343, Issue 1, October 2026.
ABSTRACT Interleukin (IL)‐10‐producing B cells represent an archetype for the regulatory functions of B cells. Here, we review the cell‐surface receptors and transcriptional regulators that control IL‐10 expression in B cells and enable their regulatory function in vivo.
Bui Thi Cuc, Yanli Tong, Zhiguo Wu, Daniel Alvarez‐Simon, Simon Fillatreau   +4 more
wiley   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk

, 2018
Btk is an attractive target for the treatment of a range of Bcell malignancies as well as several autoimmune diseases such as murine lupus and rheumatoid arthritis.
Qiu, Hui (author), Grenningloh, Roland (author), Neagu, Constantin (author), Johnson, Theresa (author), Caldwell, Richard (author), Liu-Bujalski, Lesley (author), Morandi, Federica (author), Goutopoulos, Andreas (author), Head, Jared (author), Gardberg, Anna (author), Jones, Reinaldo (author), Sherer, Brian (author), Mochalkin, Igor (author), Follis, Ariele Viacava (author)   +13 more
core   +1 more source